MemoHoney Official Website › Articles › Ingredient histories

Ingredient histories

How Citrulline Reached A Memory Label

Prepared by the MemoHoney Team, Memohonaey · First published September 21, 2026 · Reviewed for medical accuracy by Dr. Neelum Aggarwal, MD · Last revised September 30, 2026

An odd ingredient to find on a memory label

Citrulline is a watermelon compound that spent most of its research career in two places: hospital nutrition, where it is a marker of intestinal function, and the sports aisle, where it is sold by the scoop to people hoping to do one more repetition.

It now appears on memory labels, including this one, twice over: once as the hydrochloride and once bound to malic acid. That is a considerable migration for a single molecule, and it happened without a trial of citrulline in people worried about their memory.

This article is about how an ingredient makes that journey, because the route is the same for most of the shelf and knowing it is worth more than knowing about any one compound.

Step one: a real pharmacological finding

The migration always starts somewhere genuine, and here it starts with a problem in a different ingredient.

Arginine is the substrate an enzyme converts into nitric oxide, the gas that relaxes blood vessels. The trouble is that swallowed arginine mostly does not arrive: enzymes in the gut wall and the liver take a large share of an oral dose before it reaches the general circulation, which is what the labelled-meal work followed through the body.

Citrulline solves that neatly. It is absorbed largely intact, passes the liver, and is converted to arginine at the kidney. Human work on citrulline availability established how much can be given, and later pharmacokinetic work characterised the conversion step by step. Gram for gram it raises plasma arginine more reliably than arginine itself does.

That is a solid, uncontroversial finding, and it is the engine of everything that follows.

Step two: an outcome in a real population

A pharmacological finding is not a selling point until it moves an outcome, and citrulline's outcome is blood pressure.

A 2025 systematic review and meta-analysis of citrulline supplementation and watermelon intake in middle-aged and older adults reported a modest reduction in blood pressure. A 2019 review in Nutrients covering both arginine and citrulline reaches a compatible place. Neither effect is dramatic, and both are genuine.

Alongside that sits the exercise literature, which is where the volume of trials is. Citrulline malate, the form on this label, is the one those trials mostly used: three days of it before repeated sprints, a pilot setting 8 g against 12 g, and a small trial in physically active older women which gave 3 g a day alongside six weeks of training.

Note the amounts in every one of those. Three grams is the smallest, and it arrived beside supervised exercise.

Five trials, five populations, and not one of them measured memory in people who were worried about it.

Step three: the jump to a new category

Here is where the migration happens, and it happens in a single sentence that nobody has to write down.

The brain takes about a fifth of the body's oxygen budget at rest. An organ that hungry is plausibly the first to notice when delivery is sluggish. Therefore an ingredient that improves delivery might help an organ that depends on it. Therefore a memory label.

Every step of that is reasonable and the conclusion is a hypothesis rather than a finding. The nearest thing to a test is one trial that measured cerebrovascular function directly, at 8.8 g a day for five days, in taekwondo athletes during sprint interval training. It is a real measurement of blood flow to the head and it is a long way from a capsule taken at breakfast by somebody in their fifties.

What has not happened, for citrulline or for the finished formula it sits in, is a randomised trial with a cognitive outcome in the population that buys it. That is not a scandal. It is the ordinary state of this whole shelf, and it is why the one large, long, properly powered trial in this field is still the most instructive thing in it: after decades of encouraging smaller studies, ginkgo produced no reduction in dementia across more than three thousand older adults followed for a median 6.1 years.

What the migration costs in evidence

Three things are quietly lost when an ingredient crosses categories, and all three are worth naming because they are invisible on a label.

The population changes. A result in athletes during sprint intervals is a result under conditions of high demand and high flow. Whether it generalises to a sedentary fifty-five-year-old at breakfast is an empirical question that nobody has answered.

The outcome changes. Blood pressure, arterial stiffness and flow velocity are not memory. The distance between a vascular measurement and a cognitive one can be enormous, which is exactly what the one large trial that treated blood pressure hard and then measured dementia was built to find out.

And the amount changes, usually by an order of magnitude. Every trial in the table above is written in grams. A capsule holds well under one gram in total, and this one shares that space between six ingredients.

The same route, walked by half this shelf

Citrulline is the clearest case because its paper trail is unusually tidy, but the route is not unusual. Three other ingredients on this bottle reached it the same way.

Arginine AKG came out of the pre-workout aisle, where it was sold on the theory that the salt survives absorption better than plain arginine. Its trials are pharmacokinetic and performance trials in trained young men, at 12 g a day, and a single 3 g dose before one session moved nothing that was measured.

Beta-alanine came from the same aisle by an even longer route: it raises muscle carnosine, carnosine buffers acid, and acid buffering helps a set of squats. The bridge to a brain label is that carnosine is also present in brain tissue, and one imaging trial in older adults reported a change in a white-matter measurement.

Niacin travelled the other way entirely, from vitamin deficiency research. Severe deficiency causes pellagra, whose third classical symptom is dementia, and a large dietary cohort reported that the lowest intakes carried the highest rate of incident Alzheimer's disease. That is a real observation about deficiency and it is not an argument that more is better in somebody who is not deficient.

How to read an ingredient that has migrated

Not with contempt, which is the easy response and usually the wrong one. The chemistry underneath this migration is real, the absorption advantage of citrulline over arginine is well established, and a formula built on it is a more thoughtful thing than a formula built on whatever was cheap.

Read it as a hypothesis with an unknown dose. That is the accurate description, and it leads somewhere useful: find the trial amount, compare it with what a capsule can hold, and decide what you think the residue is worth. The comparison table on this website does the first two of those for all six ingredients on this label.

And hold the alternative in view. A plain daily multivitamin, which nobody markets with a mechanism, has two randomised trials reporting memory benefits in older adults. The unglamorous option is often the better-evidenced one in this field, and a website selling the glamorous one is the right place to say so.

A good molecule, a long way from home

Citrulline is not a bad ingredient and its presence on this label is not a trick. It is a well-understood compound with a genuine absorption advantage, a modest blood-pressure effect at gram amounts, and one trial that measured blood flow to the head in athletes.

What it does not have is a memory trial, and what this label does not have is a number. Those two absences together are the honest summary of why a watermelon compound ended up on a memory bottle, and of how far anybody should carry a sports-nutrition result across.

The mechanism page follows the rest of the pathway, and the fit page sets out who should be looking at something else entirely.